Drug Profile
Research programme: cancer stem cell therapeutics - OncoCyte
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator OncoCyte Corporation
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 May 2015 Preclinical development is ongoing in USA (Parenteral) (OncoCyte, website, May 2015)
- 26 Jan 2015 OncoCyte Corporation receives patent allowance for applications of stem cells to cancer therapeutics in USA